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Summary
In order to discover whether laboratories have policies
regarding the testing of unaffected children, we surveyed
all laboratories registered with Helix, a national net-
work of DNA diagnostic laboratories. Of 186
laboratories asked to respond anonymously to a four-
page questionnaire, 156 (84%) replied. A screening
question removed 51 laboratories that provided no
clinical services. Of the remaining 105, 92% said that
their requisition forms asked the person’s age.
Substantial minorities had policies for the testing of
minors for late-onset disorders (46%), for carrier status
for recessive disorders (33%), or for disorders for which
the test offers no medical benefit within 3 years (33%).
Most laboratories are responsive to parental requests.
For 12 of 13 late-onset disorders, the majority of
laboratories that offered testing had had requests to test
children. The majority had tested healthy children, !12
years of age, for eight disorders. Approximately 22%
had tested children, !12 years of age, for Huntington
disease. Majorities had received requests to test healthy
children for carrier status for 10 of 15 recessive or X-
linked disorders and had tested children, !12 years of
age, for 6 of these disorders, including cystic fibrosis,
hemophilia A, fragile X syndrome, and Duchenne
muscular dystrophy. Approximately 45% of the
laboratories occasionally had provided tests directly to
consumers. In view of the possibility that the harms of
presymptomatic diagnoses of children sometimes may
outweigh the benefits, our results suggest a need for
consistent laboratory policies designed for the best
interests of the child and the family.
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Introduction
The genetic testing of children may have numerous di-
agnostic and prognostic applications for those who al-
ready have symptoms or who may develop them in the
near future. However, parental requests for genetic test-
ing of unaffected children and adolescents have raised
a number of ethical issues and have led to several state-
ments by professional organizations. In the past several
years, the boards of directors of The American Society
of Human Genetics (ASHG) and the American College
of Medical Genetics (ACMG), the Council on Ethical
and Judicial Affairs of the American Medical Associa-
tion (AMA), and, in Britain, the Clinical Genetics Society
(CGS) have published statements on this issue (CGS
1994; AMA 1995; ASHG and ACMG 1995).
The most ethically worrisome situations involve the
testing of asymptomatic children for (1) genes for a later-
onset disorder, when there is no medical benefit to the
child in the near future, and (2) carrier status for a re-
cessive or X-linked disorder, when the information is not
immediately useful for the child’s reproductive decision
making. The statements by the ASHG and ACMG
(1995), the AMA (1995), and the CGS (1994) all have
expressed caution regarding the testing of minors, in
these two situations, especially if the request is from the
parents rather than from the child. The International
Huntington Association and the World Federation of
Neurology have issued a policy statement recommending
that minors not be tested for Huntington disease (Bloch
and Hayden 1990; Went 1990). Some authors, in both
the United States and the United Kingdom, have rec-
ommended that testing be performed only if there is a
clear benefit for the minor (Harper and Clarke 1990;
Institute of Medicine 1994; Clarke and Flinter 1996).
Requests for the presymptomatic and the carrier test-
ing of children are likely to increase. In a recent survey
of 1,084 U.S. genetics-services providers, 44% reported
that they had had requests to test children for adult-
onset disorders (Wertz 1995). Few geneticists reported
that they would test for Huntington disease or Alzheimer
disease. Although a lesser portion (20%) of 499 U.S.
primary-care physicians surveyed reported such re-
quests, the majority thought that parents should be able
to have their minor children tested for Huntington dis-
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ease (66%) and for Alzheimer disease (58%) (Wertz
1996). In a recent survey of 988 members of the adult
general public, conducted by Roper-Starch Worldwide,
53% thought that parents should “be able to have their
children under 18 tested for genetic conditions that may
appear much later in life,” even if the condition was
“neither preventable nor treatable” (Wertz 1996), al-
though the question included a statement that the in-
formation from the test “might lead to emotional prob-
lems or cause people to be prejudiced against the child”
(Roper-Starch Worldwide, personal communication)
similar pattern appeared in studies performed in the
United Kingdom, with nongeneticist physicians more
willing to provide testing than were geneticists (CGS
1994).
Except for newborn screening, neither state nor fed-
eral law regulates laboratories’ practices concerning the
testing of children, in routine clinical settings. However,
laboratories routinely do provide technical assistance to
physicians, concerning the appropriateness of genetic
testing in various cases. Laboratories therefore could
play an important role in ensuring that genetic tests are
applied to minors appropriately.
Subjects And Methods
In order to discover whether laboratories that offer
genetic tests (1) have policies regarding the testing of
asymptomatic children and adolescents, (2) have had
parental requests to test asymptomatic children for later-
onset disorders or for carrier status, (3) have fulfilled
such requests, and (4) would honor requests coming di-
rectly from adolescents, we surveyed all members of He-
lix, a national directory of DNA diagnostic laboratories,
which is self-described as “a current listing of fee-for-
service and research laboratories performingdisease-spe-
cific testing of heritable disorders” (Helix 1995, p. 1).
At the time of the survey, in October 1994, 186 labo-
ratories were listed by individual registrants who were
health-care professionals. We sent each registrant a four-
page questionnaire regarding the genetic testing of chil-
dren. There were three waves of mailings. All question-
naires were answered anonymously.
Results
In all, 156 (84%) laboratories returned question-
naires. Of these, 51 reported, in answer to an initial
screening question, that they tested for research purposes
only and that they offered no clinical testing. They were
asked to go no further with the questionnaire. The re-
maining questions in the survey applied only to testing
for clinical purposes. Of the 105 laboratories that of-
fered clinical testing, 92% reported that their requisition
forms asked for age, and 55% reported that they had
refused to test a minor’s sample, on at least one occasion.
Almost one-half (46%) reported that they had policies
for the testing of children or adolescents for late-onset
disorders; but these policies varied widely. Thirty-three
percent had policies for testing either for disorders when
there is no apparent health benefit in the near future
(0–3 years) or for carrier status for recessive disorders.
When asked what these policies were, 25 laboratories
reported that they do not test unless there is a medical
benefit; 11 reported that they decide on a case-by-case
basis; 9 reported that they do not test for Huntington
disease, including 5 that referred to the guidelines of the
ASHG, the Institute of Medicine, the Huntington Dis-
ease Society of America, or the Canadian Huntington
Disease Collaborative; 8 reported that they test at the
parents’ request, after counseling; and 7 reported that
they do not test for adult-onset disorders but will test
for carrier status, at the parents’ request. Some labo-
ratories (18%) had been called by physician clients who
expressed concern about the ethics of the testing of chil-
dren or adolescents; reports of physicians’ concerns ap-
peared to be distributed equally across the minors’ ages.
A minority (26%) of respondents thought that “par-
ents should always have a right to request tests on behalf
of their minor (less than 18 years old) children, even if
the child objects.” When it is assumed that the child
does not object, however, 61% of respondents would
process a sample for cystic fibrosis carrier testing, for
parents who request the testing of a 7-year-old. In all,
on some occasions, 45% had “provided testing if re-
quested directly by a consumer rather than a physician.”
The questionnaire listed 13 later-onset disorders and
asked whether respondents offered clinical tests for these
disorders. It was assumed that the responses applied to
clinically and analytically validated tests, although val-
idation standards vary among labs. For 12 of the 13
disorders listed, a majority of the laboratories that of-
fered a test had had requests to test healthy children or
adolescents (table 1). For 8 of the 13 disorders, a ma-
jority of the laboratories that offered a test actually had
tested healthy children or adolescents (table 1).
With the exception of those testing for Huntington
disease, few laboratories reported ever having refused to
test on the basis of the age of the patient. For 10 of the
13 disorders, there were no reported refusals. Of those
who offered tests, 44% had refused to test children for
Huntington disease, 17% had refused to test for familial
polyposis coli, and 6% had refused to test for myotonic
dystrophy.
The questionnaire listed 15 autosomal recessive or X-
linked disorders and asked respondents whether they
had ever been requested to perform, and whether they
had performed or refused to perform, “tests to determine
carrier status in healthy unaffected children or adoles-
cents under age 18.” The response data appear in table
2. For 11 of the 15 disorders, the majority of the lab-
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Table 1
Testing of Asymptomatic Children, for Later-Onset Disorders
DISORDER (n)a
PERCENTAGE OF LABORATORIES THAT
PERCENTAGE OF LABORATORIES THAT TESTED
CHILDREN OF THE AGES OF
Had Requests to Test
Children Tested Children !12 Years 12–14 Years 15–17 Years
Retinitis pigmentosa (5) 100 80 80 80 80
Spinal muscular atrophy (12) 92 75 67 25 25
Marfan syndrome (8) 75 75 75 88 50
Myotonic dystrophy (32) 84 72 59 38 34
Charcot-Marie-Tooth disease (9) 77 66 44 33 33
Neurofibromatosis (17) 65 65 65 47 29
Hypertrophic obstructive cardiomyopathy (5) 60 60 40 60 60
von Hippel–Lindau disease (7) 86 57 57 43 29
Familial hypercholesterolemia (4) 75 50 50 50 50
Facioscapulohumeral muscular dystrophy (6) 50 50 33 17 33
Familial polyposis coli (12) 58 42 33 25 17
Adult polycystic kidney disease (17) 53 41 35 12 18
Huntington disease (36) 56 28 22 19 17
a n  no. of laboratories that offered testing for the disorder.
oratories that offered a test had had requests to test
healthy unaffected children or adolescents for carrier
status. For 6 of the 15 disorders, including 5 that are
X-linked, the majority of the labs that offered a test
reported actually having tested healthy girls, !12 years
of age, for carrier status. Few laboratories reported ever
refusing to test for carrier status on the basis of the age
of the patient. For 10 of the 15 disorders, there were no
reported refusals. Five percent reported refusing to test
for Tay-Sachs disease, fragile X syndrome, and cystic
fibrosis, 16% had refused to test for Duchenne muscular
dystrophy, and one laboratory (25%) had refused to test
for choroideremia.
The age of 16 years appears to be the turning point
at which many respondents thought “adolescents should
be able to request tests on their own.” Fifty percent
favored the ages of 16–17 years, as compared with 27%
who favored the ages of 14–15 years, and 15% thought
that adolescents should not be able to request tests until
they reach majority. When presented with a hypothetical
case, most laboratories reported that they would process
a sample for cystic fibrosis carrier testing at the request
of a 16-year-old, whether the individual was married
(93%) or unmarried (84%).
Discussion
The data suggest that most laboratories had no com-
prehensive policies. On the other hand, 55% had refused
to test a minor on at least one occasion. This suggests
that many laboratories were concerned about the pos-
sible effects of testing. In the absence of research on
children who have been tested and on their families, it
is impossible to weigh empirically the balance between
the benefits and the harms of testing. In the case of
familial polyposis coli, early testing can rule out periodic
sigmoidoscopies, for one-half the children, and may help
the rest to prepare psychologically for possible surgeries
(Peterson 1993). Research on older adolescents tested
for Tay-Sachs carrier status has indicated that the ma-
jority of those tested showed no measurable psychoso-
cial harms from learning their carrier status (Clow and
Scriver 1977a, 1977b). However, several years later,
19% of the carriers still were worried about this infor-
mation (Zeesman et al. 1984). We have described else-
where the possible, but as yet unproved, psychological
and familial harms (Wertz et al. 1994).
Professional-society statements and the Task Force on
Genetic Testing (in press) have pointed to threats to the
child’s autonomy. Premature testing forecloses the pos-
sibility that the child, when an adult, may not wish to
be tested and thus denies the future autonomy of the
child, in favor of the present autonomy of the parents.
On the other hand, some consumer groups appear to
favor the parents’ rights to testing (Genetic Interest
Group 1996), on the basis that parents are better able
to predict the psychosocial outcomes of testing than are
physicians. Parents’ groups have differentiated between
carrier testing, which they favor, and presymptomatic
testing, which they consider to be harmful. They argue
that testing for carrier status may be less traumatic in
childhood than in adolescence (when the minor may
become reproductively active and may seek testing any-
way) and that such testing may reduce anxiety and is
not stigmatizing if the family is educated sufficiently,
through counseling.
The wide variation among laboratories, with regard
to the performance of tests and the ages at which tests
were performed, suggests the need for a consistent policy
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Table 2
Testing of Asymptomatic Children, for Carrier Status for Recessive Disorders
DISORDER (n)a
PERCENTAGE OF LABORATORIES THAT
PERCENTAGE OF LABORATORIES THAT TESTED
CHILDREN OF THE AGES OF
Had Requests to Test
Children Tested Children !12 Years 12–14 Years 15–17 Years
Fragile X syndrome (64) 84 78 66 63 67
G6PD deficiency (4) 75 75 75 75 75
Duchenne muscular dystrophy (37) 86 68 51 46 51
Cystic fibrosis (47) 81 68 57 53 53
Adrenoleukodystrophy (8) 88 63 63 38 38
Hemophilia A (26) 69 54 58 42 42
Retinitis pigmentosa (6) 83 50 50 50 50
b-Thalassemia (18) 44 44 33 22 17
Fabry disease (7) 86 43 29 43 29
Tay-Sachs disease (19) 53 42 42 32 32
Spinal muscular atrophy (14) 71 36 29 7 7
Sickle-cell anemia (34) 35 29 24 12 15
Choroideremia (4) 25 25 25 25 25
Norrie disease (5) 60 20 20 20 20
a-1-Antitrypsin deficiency (11) 36 9 18 9 9
a n  no. of laboratories that offered testing for the disorder.
that takes into account both the best interests of the
child and the interests of the family. Although labora-
tories may not regard themselves as policy makers or as
gatekeepers, they are responsible for informing physi-
cians who order tests about the technical appropriate-
ness of a test. Laboratories routinely provide such tech-
nical assistance. They can help to educate physicians
(including the growing number of primary-care physi-
cians who order genetic tests) about the medical appro-
priateness of the testing of children of various ages.
Sometimes this maymean that the effects of carrier status
on health should be explained. For example, some pri-
mary-care physicians may believe that a cystic fibrosis
carrier test will show the cause of a child’s bronchitis.
The test is clearly inappropriate for this purpose. How-
ever, laboratories are not responsible for educating phy-
sicians. If, after receiving information about the appro-
priateness of a test, the physician still requests the test,
the laboratory presumably must comply. Requirements
for physician competence, as recommended by the Task
Force on Genetic Testing (in press), would help to pre-
vent the ordering of inappropriate tests.
Some doctors may turn to laboratories for guidance.
In our study, 18% of the laboratories reported that phy-
sicians had consulted them about ethical issues involved
in the testing of children. Although laboratories cannot
be expected to provide expertise in bioethics, they could
provide sources of information to physicians seeking
such guidance.
Approximately one-half (45%) of the laboratories had
provided testing directly to consumers, but only five of
those providing direct testing reported policies that re-
quired pretest counseling, at least in some situations.
This is an area in which public health regulation re-
quiring counseling may be appropriate, at least in states
that permit consumers to approach laboratories directly.
Although adults who have experience with a genetic dis-
order in a close relative sometimes may wish to avoid
what they regard as unnecessary counseling sessions and
may prefer to interact directly with a laboratory, children
cannot make this kind of choice. The state has a duty
to protect children. This duty could be met by the re-
quirement of pretest counseling for the parent and the
child, as well as posttest counseling and follow-up if the
test is performed, for cases concerning the presympto-
matic testing of children when there is no medical benefit
expected at age !18 years.
A basic problem is that there are no standards or
requirements to be met when new tests are placed into
service. The final recommendations of the Task Force
on Genetic Testing (submitted for publication May 19,
1997) deal with the issue of technical standards but do
not comment in depth on presymptomatic and carrier
testing of children, noting only that the “genetic testing
of children for adult onset diseases should not be un-
dertaken unless direct medical benefit will accrue to the
child, and this benefit would be lost by waiting until the
child has reached adulthood” (Task Force on Genetic
Testing, in press).
Our survey results suggest a clear need for compre-
hensive and consistent policies. Although 2 years have
elapsed since the survey was conducted, there is, as yet,
no evidence of such policies. Most policy on health-care
delivery is made at three levels: by law, by regulations
issued by governmental agencies, or by professional self-
regulation. Laws make the most stringent rules but are
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sometimes too inflexible. In medicine, there are always
exceptions—for example, the family in which Hunting-
ton disease appears in childhood and in which the pa-
tient’s adolescent siblings desire testing or the family in
which the sisters of a boy with fragile X syndrome ask
for testing, because they are doing poorly in school. In
such situations, the benefits of testing may outweigh the
harms, but a law such as that in Norway (1994) would
forbid it. There are few regulations regarding genetics,
at the state level. Even regulations on newborn screening
are uneven; after 35 years of screening, a mature and
consistent set of regulations has not emerged. A policy
would make little sense if clients could circumvent it by
crossing state lines.
For now, we suggest that the appropriate professional
organizations, such as the American Academy of Pedi-
atrics and the ACMG, develop detailed guidelines for
the genetic testing of children, periodically reevaluate
them, and ask laboratories to follow them. Self-regu-
lation by professional societies has the advantage of pol-
icy formulation by those most familiar with the needs
of parents and children and is also the most flexible
approach. One disadvantage is that members of one pro-
fessional organization may not be aware of or attach
weight to the position papers put forward by other
organizations.
However, at least some laboratories in our survey paid
attention to professional-society statements. The most
frequently reported situation for the refusal to test was
when testing for Huntington disease was requested, with
44% of the laboratories that offered such tests refusing
to test minors. Huntington disease was one of the few
disorders for which national and international profes-
sional associations had published guidelines, at the time
of the survey.
The best way to achieve consistent policies may be to
foster consultation among regional genetics groups, ge-
neticists, pediatricians, family practitioners, and their lo-
cal and national professional societies; state public-
health departments; and consumers. Policies could be
bolstered by regulations requiring parental informed-
consent forms, children’s assent forms, and evidence that
the family has been offered counseling with a trained
professional, before testing.
In view of the limited number of genetics profession-
als, much genetic testing ultimately will be provided by
primary-care physicians. The majority of primary-care
physicians believe that parents should be able to have
their minor children tested for all genetic disorders, in-
cluding untreatable adult-onset disorders such as
Huntington disease or Alzheimer disease (Wertz 1996).
The majority of the U.S. public apparently agrees
(Roper-Starch Worldwide, personal communication). As
there is more pressure—from primary-care physicians,
parents, the health-care system, and, sometimes, ado-
lescents themselves—to test children and adolescents,
there will be a growing need for policies that work in
the best interests of the child. Laboratories, as potential
gatekeepers, could play an essential role in the devel-
opment of such policies.
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